Biogen Idec Inc. / Elan Corporation plc (Tysabri rights)

Multiple Sclerosis (relapsing forms) and Crohn's Disease

Disease Overview

Multiple sclerosis is an autoimmune demyelinating disease of the CNS affecting roughly 1 million Americans, with relapsing-remitting MS the most common form. Tysabri (natalizumab) is a humanized anti-alpha-4 integrin monoclonal antibody that blocks lymphocyte trafficking across the blood-brain barrier, delivering best-in-class efficacy on relapse rate and MRI activity but carrying a labeled risk of progressive multifocal leukoencephalopathy (PML) tied to JC virus seropositivity, prior immunosuppressant use, and treatment duration.

Competitive Landscape

By April 2013, Tysabri sat at the high-efficacy end of the MS market alongside injectable platform therapies — Biogen's own Avonex (interferon beta-1a), Teva's Copaxone (glatiramer acetate), Bayer's Betaseron, and Merck KGaA's Rebif — and faced rapidly emerging oral DMTs led by Novartis's Gilenya (fingolimod, approved 2010) and Sanofi/Genzyme's Aubagio (teriflunomide, 2012). Biogen's own Tecfidera (dimethyl fumarate) launched in March 2013 just weeks before this deal closed and would dominate the oral DMT segment. The transaction replaced the prior 50/50 Biogen-Elan profit-sharing arrangement with a $3.25B upfront plus tiered royalties (12% in year 1, then 18%/25% as sales scaled) and gave Biogen full strategic and commercial control. Biogen guided the deal as $0.20-$0.30 GAAP and $0.50-$0.60 non-GAAP accretive in 2013. Strategically, the buyout consolidated MS franchise economics under one roof at the same moment Tecfidera was poised to take volume from interferons, hedging Biogen's portfolio against intra-class cannibalization while preserving upside in patients who stay on or escalate to Tysabri after JC virus risk stratification.